TABLE 6.
Baseline characteristics of propensity score‐matched pairs
| Variable | APD‐1 (n = 49) | BRAF/MEKi (n = 49) |
|---|---|---|
| Median age at 1L initiation, years (range) | 58 (26, 90+) | 64 (40, 90+) |
| Race, n (%) | ||
| White | 44 (89.8) | 45 (91.8) |
| Unknown | 3 (6.1) | 4 (8.2) |
| Other | 2 (4.1) | 0 (0.0) |
| Male sex, n (%) | 32 (65.3) | 33 (67.3) |
| Median follow‐up time from 1L initiation, months (range) | 11.3 (0.4, 40.5) | 11.8 (0.9, 42.3) |
| ECOG performance status at 1L initiation, n (%) | ||
| 0‐1 | 34 (69.4) | 33 (67.3) |
| 2+ | 3 (6.1) | 5 (10.2) |
| Not documented | 12 (24.5) | 11 (22.4) |
| Stage at diagnosis, n (%) | ||
| Stage I/II | 5 (10.2) | 5 (10.2) |
| Stage III/IV | 36 (73.5) | 35 (71.4) |
| Not documented | 8 (16.3) | 9 (18.4) |
| PD‐L1 status, n (%) | ||
| Positive | 5 (10.2) | 1 (2.0) |
| Negative | 7 (14.3) | 3 (6.1) |
| Not documented | 37 (75.5) | 45 (91.8) |
| LDH status at 1L initiation, n (%) | ||
| Normal | 22 (44.9) | 26 (53.1) |
| Elevated | 8 (16.3) | 10 (20.4) |
| Not documented | 19 (38.8) | 13 (26.5) |
| Sites of metastases at 1L initiation, n (%) | ||
| Other | 32 (65.3) | 28 (57.1) |
| Lung | 19 (38.8) | 21 (42.9) |
| Bone | 12 (24.5) | 15 (30.6) |
| Brain | 13 (26.5) | 14 (28.6) |
| Liver | 7 (14.3) | 9 (18.4) |
| Prior radiation and brain metastases at 1L initiation, n (%) | 10 (20.4) | 10 (20.4) |
| Metastatic status at 1L initiation, n (%) | ||
| M0 | 0 (0.0) | 1 (2.0) |
| M1a | 6 (12.2) | 5 (10.2) |
| M1b | 7 (14.3) | 5 (10.2) |
| M1c | 32 (65.3) | 32 (65.3) |
| Mx | 4 (8.2) | 6 (12.2) |
Abbreviations: 1L, first‐line; aPD‐1, anti‐PD‐1 monotherapies; BRAF/MEKi, BRAF/MEK inhibitors; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD‐L1, programmed death ligand‐1.